ReviewCancers2026
Predictive Biomarkers of Systemic Therapy Response in Cutaneous Melanoma.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Late-stage cutaneous melanoma management has already evolved into systemic therapy thanks to the fast development of novel targeted inhibitors and immune checkpoint blockers. Therefore, a reliable prediction of systemic therapy response became crucial for making a personalised management plan for melanoma patients. Although there are multiple biomarkers already available, the overall predictive confidence remains low due to heterogeneous responses among patients. Therefore, novel solid predictive biomarkers are still greatly needed. With the development of new technologies and artificial intelligence, new predictive models are being proposed and generated. In this review, we thoroughly evaluated the established biomarkers that are already in use for clinical practice. In addition, we proposed the emerging new markers with great potential by critically reviewing the literature. Furthermore, we proposed a future framework for making a tailored clinical management plan for melanoma patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.